ARCA Biopharma, European Patent for Gencaro and Q3 Review

ARCA Biopharma, European Patent for Gencaro and Q3 Review

Arca Biopharma (NASDAQ: ABIO) up over 150% following our initial report here (updated 01/07/21)

ARCA Biopharma, Inc. (NASDAQ: ABIO), is a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in chronic heart failure patients with reduced left ventricular ejection fraction.

ARCA and Medtronic, Inc. have entered into a collaboration to support GENETIC-AF, ARCA’s Phase 2B clinical trial evaluating Gencaro as a potential treatment for atrial fibrillation. Medtronic uses its proprietary CareLink System to collect and analyze the cardiac rhythm data from the implanted Medtronic devices of a substudy of patients participating in GENETIC-AF. Medtronic is the world’s largest medical technology company and a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders.

Recent Events

November 16, 2017. ARCA announced the European Patent Office’s issuance of a patent (EPO # 2515899) on methods of treating cardiovascular disease and conditions with a thiol-substituted isosorbide mononitrate based on genetic targeting.  The European patent, entitled “Methods and Compositions for Cardiovascular Diseases and Conditions,” provides protection for this novel approach to treating patients with cardiovascular disease and conditions.  The European patent has been validated in ten countries: Denmark, France, Germany, Ireland, Italy, Netherlands, Spain, Sweden, Switzerland, and the United Kingdom.  ARCA has related patent applications pending in the United States Patent Office and Canadian Intellectual Property Office.


The ABIO lead product candidate, Gencaro™ (bucindolol hydrochloride), is a pharmacologically unique beta-blocker and mild vasodilator the company is evaluating in a clinical trial for the treatment and prevention of recurrent atrial fibrillation, or AF, in patients with heart failure with reduced left ventricular ejection fraction, or HFREF.

Beta-blockers, a well characterized class of drugs, target cardiac myocytes to reduce adverse beta1- adrenergic signaling that causes cardiac chamber remodeling. Gencaro’s mechanism of action (MOA) is unique among beta-blockers due to its sympatholytic (norepinephrine lowering) and inverse agonism (inactivation of constitutively active receptors) properties.

ABIO has identified common genetic variations in receptors in the cardiovascular system they believe interact with Gencaro’s pharmacology and may predict patient response to the drug. The genotype which responds most favorably to Gencaro, beta-1 389 arginine homozygous, is present in approximately 50% of the U.S. population.



ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases through a precision medicine approach to drug development.  ARCA’s lead product candidate, GencaroTM (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the potential treatment of patients with atrial fibrillation and HFrEF, currently in a Phase 2B clinical trial.  ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted atrial fibrillation prevention treatment.  ARCA has a collaboration with Medtronic, Inc. for support of the GENETIC-AF trial. The Gencaro development program has been granted Fast Track designation by the FDA.

Third Quarter 2017 Summary Financial Results

Cash, cash equivalents and marketable securities totaled $16.0 million as of September 30, 2017, compared to $23.5 million as of December 31, 2016.  ARCA had approximately 11.75 million outstanding shares of common stock as of September 30, 2017.  ARCA believes that its current cash, cash equivalents and marketable securities will be sufficient to fund its operations, at its projected cost structure, through the end of second quarter of 2018.

Research and development (R&D) expenses for the three months ended September 30, 2017 totaled $3.5 million compared to $3.7 million for the corresponding period of 2016, a decrease of approximately $0.2 million.  R&D expense for the nine months ended September 30, 2017 totaled $11.2 million compared to $9.2 million for the corresponding period of 2016, an increase of approximately $2.0 million.

General and administrative (G&A) expenses for the three months ended September 30, 2017 were $1.0 million compared to $1.0 million for the corresponding period in 2016.  G&A expenses totaled $3.2 million for the nine months ended September 30, 2017 as compared to $3.1 million for the corresponding period in 2016, a net increase of approximately $79,000

Total operating expenses for the three months ended September 30, 2017 were $4.5 million compared to $4.7 million for the corresponding period in 2016.  Total operating expenses for the nine months ended September 30, 2017 were $14.4 million compared to $12.3 million for the corresponding period in 2016.

Net loss was $4.4 million, or $0.39 per share, for the third quarter of 2017 compared to $4.7 million, or $0.51 per share, for the third quarter of 2016.  Net loss for the nine months ended September 30, 2017 was $14.3 million, or $1.43 per share, compared to $12.2 million, or $1.35 per share, for the corresponding period in 2016.

Stock Influences and Risk Factors

Any positive new from the FDA would be a significant catalyst

Positive Phase 2B trial data would be a catalyst

If they encounter difficulties enrolling patients in clinical trials, the trials could be delayed or otherwise adversely affected.

If they are not able to develop, obtain FDA approval for, and provide for the commercialization of Gencaro in a timely manner, they may not be able to continue our business operations.

They may not achieve projected development goals in the time frames announced.

Failure to raise substantial additional funding or enter into a strategic transaction may materially and adversely affect the business.

Stock Chart

On Thursday, November 16, 2017, ABIO shares were trading at $1.50 (+25%) on traded volume of 1.7 million shares. The current RSI (14) is 65.09

At $1.50, ABIO shares are trading above their 50-day moving average of $1.28 and below their 200-day moving average of $2.01.

Traders News Source Recent Track Record


Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Traders News Source has not been compensated for this report by anyone and the opinions if any are that of the author Vikas Agrawal, CFA. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.
This web site, published by TNS LLC, and is an investment newsletter that is built on the premise of assisting individual investors in learning about investing. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers. TNS LLC does not give buy or sell recommendations. We do purchase distribution rights from analyst, financial writers and bloggers for a fee that may be licensed to issue price targets and recommendations. Furthermore, we encourage you to speak to a licensed professional prior to making an investment in any type of publicly traded security.
We do sell advertising to other companies including brokerage firms, web sites, publicly traded issuers, investor relations firms, and investment publications, among others. TNS LLC makes no warranty as to the policies of these organizations, and in no way endorses their offers, services, or the content of their advertisements.
When an advertiser is a publicly traded company or a third party acting on behalf of a public company, we fully disclose all compensation in the email advertisement. Such disclosure is included in a disclosure statement in each of the advertisements sent via email.
17B Disclosure
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur.
Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.